Li Kong
- Oncology top 1%
- Lung Cancer Research Studies 20
- Cancer Immunotherapy and Biomarkers 19
- Ophthalmology top 1%
- Retinal Diseases and Treatments 12
- Immunology top 5%
-
- Lung Cancer Treatments and Mutations 20
- Lung Cancer Diagnosis and Treatment 16
- Cancer Research top 5%
-
- Esophageal Cancer Research and Treatment 15
-
- Redox biology and oxidative stress 14
-
- Advanced Glycation End Products research 13
- Co-authors
- Feifei TengHui ZhuJinming YuXin WangFang ShiXiaohong ZhouYang LiuYinping Dong
- Cited by
- OncologyOphthalmologyImmunology
- Journals
- OncoTargets and Therapy (13 papers)Oncotarget (11 papers)International Journal of Radiation Oncology*Biology*Physics (5 papers)
- Partner nations
- ChinaUnited StatesUnited Kingdom
In The Last Decade
Li Kong
162 papers receiving 4.8k citations
Hit Papers
Peers
Comparison fields: 5 of 131
- Oncology 1.8k
- Ophthalmology 362
- Immunology 757
- Pulmonary and Respiratory Medicine 967
- Cancer Research 372
Countries citing papers authored by Li Kong
This map shows the geographic impact of Li Kong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Li Kong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Li Kong more than expected).
Fields of papers citing papers by Li Kong
This network shows the impact of papers produced by Li Kong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Li Kong. The network helps show where Li Kong may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Li Kong, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2025 | 1 | |
| 4 | 2024 | 0 | |
| 5 | 2024 | 1 | |
| 6 | 2024 | 0 | |
| 7 | 2023 | 2 | |
| 8 | 2021 | 2 | |
| 9 | 2020 | 9 | |
| 10 | 2018 | 1 | |
| 11 | 2018 | 28 | |
| 12 | Thioredoxin plays a key role in retinal neuropathy prior to endothelial damage in diabetic mice | 2017 | 1 |
| 13 | Prognostic value of the standardized uptake value maximum change calculated by dual-time-point 18F-fluorodeoxyglucose positron emission tomography imaging in patients with advanced non-small-cell lung cancer | 2016 | 1 |
| 14 | 2016 | 16 | |
| 15 | Clinical observations on acupuncture treating the patients of essential hypertension with anxiety state | 2014 | 1 |
| 16 | Effect of Lu′s Zizao Decoction on Cytokine IFN-γ and IL-10 in the Salivary Gland of Mice with Sjogren′s syndrome | 2011 | 1 |
| 17 | Protection Of Retinal Photoreceptors By Activation Of AMPK With Metformin | 2011 | 1 |
| 18 | Effect of tetramethylpyrazine and cyclosporin A on reversing multidrug resistance eruthroleukemia (K562/MDR) cells with gene transfer | 2010 | 1 |
| 19 | Anti-inflammatory effect of pigment epithelium-derived factor in DBA/2J mice. | 2009 | 44 |
| 20 | Effect of tetramethylpyrazine on reversing multidrug resistance of K562/MDR cells with gene transfer | 2009 | 1 |
About Li Kong
Li Kong is a scholar working on Clinical Biochemistry, Oncology and Ophthalmology, having authored 178 papers that have together received 4.9k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (20 papers), Lung Cancer Research Studies (20 papers), Cancer Immunotherapy and Biomarkers (19 papers), Lung Cancer Diagnosis and Treatment (16 papers), Esophageal Cancer Research and Treatment (15 papers), Redox biology and oxidative stress (14 papers), Advanced Glycation End Products research (13 papers) and Retinal Diseases and Treatments (12 papers). The work is most often cited by research in Oncology (1.8k citations), Ophthalmology (362 citations) and Immunology (757 citations). Li Kong has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Feifei Teng, Hui Zhu, Jinming Yu, Jinming Yu, Xin Wang, Fang Shi, Xiaohong Zhou, Jinming Yu, Yang Liu and Yinping Dong. Their work appears in journals such as OncoTargets and Therapy, Oncotarget, International Journal of Radiation Oncology*Biology*Physics, International Journal of Molecular Sciences and Future Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.